July 28, 2020 : DCMS #512 |
|
Letter from the Editor
 Since February we have been looking for care solutions for our patients that have been diagnosed with the coronavirus. At first we thought it was strictly a respiratory problem and all damage was to the lungs. As time has progressed, we have seen the effect COVID-19 has had on the circulatory system, and there especially seems to be a problem with younger patients and blood clots. The desire to help prevent serious effects is leading many companies to get accelerated approval for currently used medications.
This week our intern Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy, tracks the accelerated approval of a diabetes drug for reduction of death and heart failure after a heart attack.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
